GMAB.US Genmab AS

Healthcare Biotechnology USA Stocks
51.37 USD
Close of Nov 14, 2026
23.62 59.97
Market cap
USD 31.7B
P/E
44.3x
P/B
5.03x
ROE
14.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is GMAB.US undervalued?

Graham number

The Graham number of Genmab AS cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genmab AS fundamental analysis

No fundamental analysis for Genmab AS yet.

Genmab AS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genmab AS

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also develop…

Full company profile